83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population

Saved in:
Bibliographic Details
Published inImmuno-oncology technology Vol. 16; p. 100187
Main Authors Mazzarella, L., Nicolo, E., Esposito, A., Crimini, E., Tini, G., Uliano, J., Corti, C., Trillo Aliaga, P.M., Valenza, C., Repetto, M., Antonarelli, G., Minchella, I., Belli, C., Locatelli, M.A., Criscitiello, C., Curigliano, G.
Format Journal Article
LanguageEnglish
Published 01.12.2022
Online AccessGet full text

Cover

More Information
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2022.100187